Systemic and Local Levels of Lidocaine During Surgery for the Removal of Glioblastoma

Inclusion Criteria:

* \>= 18 years of age
* Preoperative imaging characteristics consistent with brain glioblastoma (magnetic resonance imaging \[MRI\] brain)
* Patients who are undergoing neurosurgical resection for treatment of glioblastoma
* Ability to understand and willingness to sign an informed consent form
* Ability to adhere to the study visit schedule and other protocol requirements

Exclusion Criteria:

* Prior treatment for glioblastoma
* Glioblastoma size less than 5 cm\^3
* Known allergy against amide type of local anesthetics
* History of severe cardiac failure (determined by clinical history of less the 3 Metabolic Equivalent of Tasks \[METs\])
* 2nd or 3rd degree heart block (exception: patients with pacemaker)
* Concurrent treatment with class I or III antiarrhythmics (phenytoin, procainamide, propranolol, quinidine) or amiodarone use =\< 3 months
* History of Wolff-Parkinson-White syndrome, Stokes Adams syndrome, or active dysrhythmia
* History of bradycardia
* Prior clinical history of severe hepatic impairment or alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 1.55 times of upper normal limit
* Prior clinical history of severe renal impairment or estimated glomerular filtration rate (EGFR) \< 30ml/min
* Uncontrolled seizure disorder
* Acute porphyria
* Patients requiring an awake fiberoptic intubation due to administration of additional lidocaine
* Pregnant or lactating women
* Any condition that would prohibit the understanding or rendering of informed consent
* Any medical condition including additional malignancies, laboratory abnormalities, or psychiatric illness that in the opinion of the investigator would prevent the subject from participating and adhering to study related procedures
* Uncontrolled concomitant disease that in the opinion of the investigator would interfere with the patient's safety or compliance on trial